Screener
Halozyme Therapeutics HALO Unrealized loss on derivative instruments, net
Unrealized loss on derivative instruments, net at other companies
Other financials
Where this comes from
Reported directly by Halozyme Therapeutics in its filing.
Tagged under the XBRL concept halo:OtherComprehensiveIncomeLossCashFlowHedgeUnrealizedHoldingGainLossBeforeAdjustmentAfterTax.
The source filing: Halozyme Therapeutics’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:11 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001159036-26-000104
| Line item | Three Months Ended / June 30, 2026 | Three Months Ended / June 30, 2025 | Six Months Ended / June 30, 2026 | Six Months Ended / June 30, 2025 |
|---|---|---|---|---|
| Net income | $229,913 | $165,160 | $379,962 | $283,255 |
| Other comprehensive income | ||||
| Unrealized (loss) gain on marketable securities, net | (73) | (35) | (76) | 154 |
| Foreign currency translation adjustment | (29) | (3) | 16 | (3) |
| Unrealized gain (loss) on derivative instruments, net | 4,161 | (27,047) | 8,183 | (34,270) |
| Realized loss on derivative instruments, net | 814 | 2,095 | 2,138 | 1,887 |
| Comprehensive income | $234,786 | $140,170 | $390,223 | $251,023 |
Item 1. Financial Statements
FAQ
- What is Halozyme Therapeutics's unrealized loss on derivative instruments, net?
- Halozyme Therapeutics (HALO) reported unrealized loss on derivative instruments, net of $4.16M in Q2 2026.
- How has Halozyme Therapeutics's unrealized loss on derivative instruments, net changed year-over-year?
- Halozyme Therapeutics's unrealized loss on derivative instruments, net increased by 115.4% year-over-year, from -$27.05M to $4.16M.
- What does unrealized loss on derivative instruments, net mean?
- Unrealized loss on derivative instruments, net as reported by Halozyme Therapeutics, Inc..
Ask your AI about Halozyme Therapeutics's unrealized loss on derivative instruments, net.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude